Perfusion Imaging

In patients with suspected coronary artery disease (CAD), dynamic myocardial computed tomography perfusion (CTP) imaging combined with coronary CT angiography (CTA) has become a comprehensive diagnostic examination technique resulting in both anatomical and quantitative functional information on myocardial blood flow, and the presence and grading of stenosis. Recently, CTP imaging has been proven to have good diagnostic accuracy for detecting myocardial ischemia, comparable to stress magnetic resonance imaging and positron emission tomography perfusion, while being superior to single photon emission computed tomography. Dynamic CTP accompanied by coronary CTA can serve as a gatekeeper for invasive workup, as it reduces unnecessary diagnostic invasive coronary angiography. Dynamic CTP also has good prognostic value for the prediction of major adverse cardiovascular events. In this article, we will provide an overview of dynamic CTP, including the basics of coronary blood flow physiology, applications and technical aspects including protocols, image acquisition and reconstruction, future perspectives, and scientific challenges. KEY POINTS: • Stress dynamic myocardial CT perfusion combined with coronary CTA is a comprehensive diagnostic examination technique resulting in both anatomical and quantitative functional information. • Dynamic CTP imaging has good diagnostic accuracy for detecting myocardial ischemia comparable to stress MRI and PET perfusion. • Dynamic CTP accompanied by coronary CTA may serve as a gatekeeper for invasive workup and can guide treatment in obstructive coronary artery disease.

Myocardial perfusion imaging plays a central role in the management of patients with known or suspected coronary artery disease (CAD) and increasingly in patients with suspected ischemia with normal coronary arteries (INOCA) as well as anomalous origins of the coronary arteries and Kawasaki disease. Stress perfusion cardiovascular magnetic resonance (CMR) is recognized by international guidelines, with several Class 1 indications for the detection of abnormal myocardial blood flow in these clinical scenarios and offers excellent diagnostic accuracy and independent prognostic value. While visual interpretation of the perfusion data is the prevailing analysis method in clinical practice, quantitative perfusion CMR is at least as accurate for the detection of significant obstructive CAD and provides a more accurate estimation of the total ischemic burden in patients with CAD. Moreover, quantitative myocardial perfusion analysis provides unique insights into the pathophysiology of myocardial ischemia, including microvascular disease in INOCA. Quantitative perfusion CMR can be fully automated, is user-independent, and may facilitate more widespread use of the modality. The aim of this Society for Cardiovascular Magnetic Resonance (SCMR) expert consensus document is to provide recommendations for the acquisition and analysis of quantitative myocardial perfusion CMR to facilitate standardization of methodology. This paper also discusses research and development goals to address current limitations, to ensure data reliability and validity, to create the basis for future multi-vendor and multicenter research, and to broaden the clinical use of quantitative perfusion CMR.

BackgroundIschemia and no obstructive coronary artery disease (INOCA) is increasingly recognized and associated with poor outcomes. The triglyceride-glucose (TyG) index is a reliable alternative measure of insulin resistance significantly linked to cardiovascular disease and adverse prognosis. We investigated the association between the TyG index and myocardial ischemia and the prognosis in INOCA patients.MethodsINOCA patients who underwent both coronary angiography and myocardial perfusion imaging (MPI) were included consecutively. All participants were divided into three groups according to TyG tertiles (T1, T2, and T3). Abnormal MPI for myocardial ischemia in individual coronary territories was defined as summed stress score (SSS) ≥ 4 and summed difference score (SDS) ≥ 2. SSS refers to the sum of all defects in the stress images, and SDS is the difference of the sum of all defects between the rest images and stress images. All patients were followed up for major adverse cardiac events (MACE).ResultsAmong 332 INOCA patients, 113 (34.0%) had abnormal MPI. Patients with higher TyG index had a higher rate of abnormal MPI (25.5% vs. 32.4% vs. 44.1%; p = 0.012). Multivariate logistic analysis showed that a high TyG index was significantly correlated with abnormal MPI in INOCA patients (OR, 1.901; 95% CI, 1.045-3.458; P = 0.035). During the median 35 months of follow-up, 83 (25%) MACE were recorded, and a higher incidence of MACE was observed in the T3 group (T3 vs. T2 vs. T1: 36.9% vs. 21.6% vs. 16.4%, respectively; p = 0.001). In multivariate Cox regression analysis, the T3 group was significantly associated with the risk of MACE compared to the T1 group (HR, 2.338; 95% CI 1.253-4.364, P = 0.008).ConclusionThis study indicates for the first time that the TyG index is significantly associated with myocardial ischemia and poor prognosis among INOCA patients.

Recent randomized controlled trials (RCTs) have expanded the role of intravenous thrombolysis (IVT) into the extended time window (beyond 4.5 h) using CT perfusion (CTP)-based patient selection. Following the inclusion of extended-window thrombolysis into the most recent edition of the American Heart Association Acute Ischemic Stroke Guidelines in 2026, these recently completed studies, EXTEND, HOPE, TRACE III, and OPTION, collectively must now inform the rapid clinical implementation of this treatment as we enter an age of precision medicine in the management of acute stroke. This mini-review seeks to address three core implementation challenges for patient selection when considering extended-window thrombolysis: (1) efforts to establish clinical pathways for patient selection should consider the phenotype of patients enrolled in extended-window thrombolysis RCTs in addition to enrollment criteria, (2) assessments of the safety of extended-window thrombolysis based on the best available evidence are reassuring, and (3) promising results from extended-window thrombolysis trials for distal and medium vessel occlusion (DMeVO) stroke patients, in concert with recent neutral endovascular therapy (EVT) trials for treating DMeVO stroke, have carved out a distinct role for IVT in this patient population. Herein, we aim to leverage the best available evidence to address these critical questions that vascular neurologists face as we work toward the clinical implementation of this trial evidence.